HomeInsightsStock Comparison

Biocon Ltd vs Laurus Labs Ltd Stock Comparison

Biocon Ltd vs Laurus Labs Ltd Stock Comparison

Last Updated on: Sep 04, 2025

Key Highlights

  • The Latest Trading Price of Biocon Ltd is ₹ 356.85 as of 07 Aug 13:53.
  • The P/E Ratio of Biocon Ltd changed from 43.4 on March 2020 to 40.4 on March 2025 . This represents a CAGR of -1.19% over 6 yearsThe P/E Ratio of Laurus Labs Ltd changed from 13.5 on March 2020 to 92.4 on March 2025 . This represents a CAGR of 37.79% over 6 years.
  • The Market Cap of Biocon Ltd changed from ₹ 32472 crore on March 2020 to ₹ 40964 crore on March 2025 . This represents a CAGR of 3.95% over 6 yearsThe Market Cap of Laurus Labs Ltd changed from ₹ 3449 crore on March 2020 to ₹ 33099 crore on March 2025 . This represents a CAGR of 45.78% over 6 years.
  • The revenue of Biocon Ltd for the Jun '25 is ₹ 4021 crore as compare to the Mar '25 revenue of ₹ 4474 crore. This represent the decline of -10.12% The revenue of Laurus Labs Ltd for the Jun '25 is ₹ 1580 crore as compare to the Mar '25 revenue of ₹ 1778 crore. This represent the decline of -11.18%.
  • The ebitda of Biocon Ltd for the Jun '25 is ₹ 828.6 crore as compare to the Mar '25 ebitda of ₹ 1135 crore. This represent the decline of -27.03% The ebitda of Laurus Labs Ltd for the Jun '25 is ₹ 392.56 crore as compare to the Mar '25 ebitda of ₹ 479.17 crore. This represent the decline of -18.08%.
  • The net profit of Biocon Ltd changed from ₹ 148.9 crore to ₹ 89.2 crore over 9 quarters. This represents a CAGR of -20.37% The net profit of Laurus Labs Ltd changed from ₹ 28.4 crore to ₹ 161.08 crore over 9 quarters. This represents a CAGR of 116.27% .
  • The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 yearsThe Dividend Payout of Laurus Labs Ltd changed from 10.13 % on March 2020 to 17.01 % on March 2025 . This represents a CAGR of 9.02% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Biocon Ltd

  • Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
  • Biocon, with its key business verticals of Generics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.
  • At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
  • Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
  • In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.

About Laurus Labs Ltd

  • Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company.
  • The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007.
  • Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007.
  • Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007.
  • Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016. Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.

Biocon Ltd News Hub

News

Biocon Ltd spurts 1.42%

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 361.15,...

Read more

03 Sep 2025 13:05

News

Biocon drops after Q1 PAT tumbles 95% YoY to Rs 31 cr

Profit before tax (PBT) dropped 91.5% to Rs 96.90 crore in Q1 FY26 compared with Rs 1145.5...

Read more

08 Aug 2025 10:28

News

Biocon Ltd slips for fifth straight session

Biocon Ltd dropped for a fifth straight session today. The stock is quoting at Rs 372.85, ...

Read more

05 Aug 2025 13:35

News

Biocon edges higher after biologics arm launches autoimmune treatment drug Nepexto in Australia

Nepexto will be promoted by Generic Health, BBL's local partner and a leading provider of ...

Read more

23 Jul 2025 10:33

News

Biocon arm gets USFDA approval for insulin, Kirsty

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to im...

Read more

16 Jul 2025 08:32

News

Biocon Ltd gains for third straight session

Biocon Ltd gained for a third straight session today. The stock is quoting at Rs 390, up 2...

Read more

15 Jul 2025 13:05

Laurus Labs Ltd News Hub

News

Laurus Labs Ltd soars 1.7%

Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 87...

Read more

03 Sep 2025 13:05

News

Volumes spurt at Laurus Labs Ltd counter

Poonawalla Fincorp Ltd, Kajaria Ceramics Ltd, Aadhar Housing Finance Ltd, SBI Life Insuran...

Read more

28 Jul 2025 11:00

News

Laurus Labs Ltd rises for third consecutive session

Laurus Labs Ltd gained for a third straight session today. The stock is quoting at Rs 893....

Read more

28 Jul 2025 13:05

News

Laurus Labs climbs on robust Q1 earnings

Gross margin improved to 59.4% in Q1 June 2025, up from 55.1% in Q1 June 2024. Profit befo...

Read more

28 Jul 2025 14:46

News

Laurus Labs to announce Quarterly Result

Laurus Labs will hold a meeting of the Board of Directors of the Company on 25 July 2025. ...

Read more

10 Jul 2025 10:29

News

Laurus Labs invests Rs 39.99 cr in Laurus Bio

Laurus Labs has invested Rs 39.99 crore and acquired 15,414 Series A2 Compulsorily Convert...

Read more

26 Jun 2025 13:24

SWOT Analysis Of Biocon Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Laurus Labs Ltd

Strength

6

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Biocon Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Laurus Labs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Biocon Ltd and Laurus Labs Ltd

Which company has a larger market capitalization, Biocon Ltd or Laurus Labs Ltd?

Market cap of Biocon Ltd is 47,716 Cr while Market cap of Laurus Labs Ltd is 47,148 Cr

What are the key factors driving the stock performance of Biocon Ltd and Laurus Labs Ltd?

The stock performance of Biocon Ltd and Laurus Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Laurus Labs Ltd?

As of September 4, 2025, the Biocon Ltd stock price is INR ₹356.9. On the other hand, Laurus Labs Ltd stock price is INR ₹873.4.

How do dividend payouts of Biocon Ltd and Laurus Labs Ltd compare?

To compare the dividend payouts of Biocon Ltd and Laurus Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions